Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Top 10 Smash hit Computer games of the Year - 2Feeling wonder every day improves our health. Here’s how to do it.
- 3Discovery of massive spider's web in Greece reveals unexpected behavior
- 4New Year's superstitions: Eating 12 grapes, avoiding laundry and other rituals that are said to bring good fortune
- 5NASA set for first crewed moon return in over half a century
- Vaccine committee votes to scrap universal hepatitis B shots for newborns despite outcry from children’s health experts
- 'No middle ground' for tackling antisemitism after Bondi Beach mass shooting, deputy FM Haskel says
- EU Commission prepares €90bn Ukraine loan despite Hungary's veto
- 'Always put others first': IDF reservist who died while on leave saves four with organ transplants
- An Investigate of 6 Creative Specialty Mixed drinks
- Artemis 2 astronauts reveal adorable zero-g indicator 'Rise' | Space photo of the day for March 31, 2026
- I visited every country by 25. Antarctica showed me how much I still hadn't seen.
- Picking Childcare Administrations for Your Loved ones
- The Specialty of Compromise: Examples from Reality
